DOCSLIB.ORG

Bleeding Disorders

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bleeding Disorders Bleeding Disorders 435 medicine teamwork [ Important | Notes | Extra | Editing file ] ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ lecture objectives: ⇨ Overview of Hemostasis. ⇨ Congenital Bleeding Disorders. ⇨ Acquired Bleeding Disorders. ⇨ Platelet Disorders (Number & Function). ⇨ Approach to the bleeding patients. ⇨ Management of Bleeding patients. ★ I highly advise you to view this 1-page lecture summary before starting the lecture. Done By​: ​Bedoor Julaidan & Nouf Altwaijri Edited by​:​ Rahaf Binabbad Revised By​:​ Luluh Alzeghayer & Ahmed Alyahya References: Slides - Master the Boards - Essential Haematology- 433 Medicine team Overview: Hemostasis Definition: - The process through which bleeding is controlled at a site of damaged or disrupted endothelium. ​ ​ A dynamic interplay between: •Cellular Components: ( Platelets & Endothelium ) ​ ​ •Plasma Proteins Components: 3 protein systems ​ ​ ​ ​ 1.Blood Coagulation ( Clot Formation ) 2.Fibrinolysis ( Clot Lysing ) 3.Anticoagulant ( Regulating ) Whenever the vascular integrity is breached (vessel injury) 3 things happen. Firstly, vasoconstriction, secondly platelet plug formation lastly ​ ​ ​ ​ blood clotting (coagulation cascade) ​ ​ Platelets: - Produced in the Bone Marrow by fragmentation of the cytoplasm of ​ ​ megakaryocytes. ​ -Each megakaryocyte form 1000 to 5000 platelets. ​ ​ -Time interval from differentiation of the human stem cell to the production of platelets ( ~ 10 days ) -Thrombopoietin → the major regulator of platelets production via ​ ​ c-MPL receptor1 (thrombopoietin is produced by liver (95%) & kidney) ​ ​ -Normal platelets counts ( 150 – 400 x 10⁹ ) -Platelets life span ( 7 – 10 days ) ​ ​ Platelets ultrastructure: Extremely small & discoid (3 x 0.5 µm in diameter) ​ Contains 3 types of storage granules: α Granules Dense Granules ( δ Granules ) Lysosomes Clotting Factors ADP & ATP Hydrolytic enzymes VWF (von willebrand factor) Serotonin ​ PDGF2 Histamine IGF13 Ionized Ca Platelets Functions: 1-Adhesion ( Platelets stick to the vessel Wall ) ​ ​ -Adhesion is through attachment of GP Ib-IX-V4 to VWF ​ ​ -VWF is synthesized in endothelial cells & megakaryocytes -VWF is stored in storage granules of endothelial cells & α granules of Platelets -VWF Rises with stress, exercise, adrenaline, infusion of DDAVP (desmopressin) 2-Aggregation ( cross linking of Platelets, platelets stick together ) ​ ​ -Aggregation is through attachment of GP IIb/IIIa receptors (found on ​ ​ platelets’ surface) to VWF and Fibrinogen (mainly fibrinogen) ​ ​ ​ 3-Release Reaction & Amplification ( aggregation formation & stabilization ) ​ ​ -Primary activation by various agonists induces intracellular signaling leading to release of α granules ​ ​ contents (platelets aggregation and stabilization), & ADP (platelets activation) from dense granules ​ ​ ​ ​ 1 Thrombopoietin receptor 2 Platelet derived growth factor 3 Insulin like growth factor 4 The GPIb-IX-V complex is a membrane receptor complex present on the platelet surface. ​ ​ ​ -Formation of Thromboxane A2 by various agonists induces intracellular signaling (potentiates platelets ​ aggregation and causes powerful vasoconstriction). ​ *normally the platelets don’t adhere to the endothelium but when there is injury in the endothelium the circulating vWf will attach to subendothelial collagen on one side, and to GP Ib of platelets on the other side. this binding will ​ ​ activate the platelets. When the platelets are activated, they change in shape and receptor becomes activated *normally it is inactive*. Follows that degranulation of platelets’ granules → fibrinogen, vWF, serotonin (which causes vasoconstriction), ADP (important for platelets activation and aggregation) and Ca ( needed in the secondary hemostasis ‘coagulation’). The activated platelets also secretes thromboxane A2 which activates further platelets and causes vasoconstriction. lastly, platelets aggregation mediated by GPIIb/IIIa receptor when it binds to fibrinogen. Many GP IIb/IIIa receptors will attach to single fibrinogen and this what makes platelet plug. Platelets Inhibitors: ● Prostacyclin (PGI₂) -Synthesized by vascular endothelial cells -Potent inhibitor of Platelets aggregation & causes vasodilation by rising cAMP ​ ​ ​ ​ -Prevents Platelets adhesion to normal vascular endothelium ​ ​ ● Nitric Oxide (NO) -Released from endothelial cells, macrophages, & Platelets -Inhibit Platelets activation & promotes vasodilation ​ ​ ​ Coagulation cascade: Intrinsic pathway: We start by factor 12 which activates factor 11. Factor 11 will activate factor 9. Factor 9 in the presence of factor 8 will activate factor 10. Extrinsic pathway: We start by factor 3 (tissue factor) that activates factor 7. Factor 7 activates factor 10 Common pathway: Starting by factor 10 that activates factor 2 (prothrombin) in the presence of factor 5. Prothrombin will activates factor 1 (fibrinogen to fibrin). -Extrinsic pathway is what gets activated in times of injury. but its activation is not sufficient and we need the intrinsic pathway but how the intrinsic pathway gets activated? when factor 7 activates factor 10 and factor 10 activates prothrombin to thrombin, thrombin will activate intrinsic pathway (thrombin activates factor 5,7,8,11,13). Factor 7 also ​ activates factor 9 -The whole idea of coagulation cascade is to generate fibrin, once we ​ ​ generate fibrin we need to cross-link fibrin molecules to stabilize ​ platelet plug in order to form clot, and how this happens? by factor 13, ​ ​ ​ ​ factor 13 enables formation of fibrin mesh ‘clot stabilization’. ​In factor 13 deficiency (rare bleeding disorder) we give them fresh frozen plasma because we don't have it concentrated. -Thrombin is responsible for multiple negative feedback loops that help to control coagulation. one of them is by activating plasminogen to plasmin that breaks fibrin mesh. Thrombin also activates antithrombin that blocks further activation of thrombin and factor 10. At the end of this phase (coagulation ​ cascade) fibrinolysis phase follows. ​ ​ So in summary: Hemostatic Phases 1.Vascular Phase 2.Platelet Phase 3.Plasma Coagulation 4.Fibrinolysis Phase Phase -Release of locally Platelets Adhesion & -Propagation of the -Termination of clotting active vasoactive Aggregation (via VWF, clotting process by the by antithrombotic control ​ ​ agents (Endothelin, ADP, TXA2) coagulation cascade of mechanisms & removal Thromboxane A2, -Formation of Platelet coagulation factors. of the clot ​ Fibrinopeptides). Plug. -Formation of Fibrin Clot. ​ ​ -Vasoconstriction at ​ ​ the site of injury reduces blood flow. ★ The main function of the primary hemostasis is to form Platelet plug ​ ​ ​ ★ The main function of the secondary hemostasis is to form fibrin clot ​ ​ ​ Hemostasis - Helpful Blood Clotting​ 4:48 mins Approach to Patient with Potential Bleeding Anticoagulants: The most famous one is warfarin, what’s its relation to vitamin K? its one of the major components of the coagulation factors especially if the patient came to you with coagulopathy and prolonged ptt with normal pt + chronic liver disease with high INR vit k is not soluble because of lack of bile so ﻋﻦ k اﻟﺪﻛﺘﻮر ﻣﻤﻜﻦ ﯾﻜﻮن ذﻛﻲ ﺑﺲ ﻣﻮ ﻛﻔﺎﯾﻪ ﻓﺎﯾﺶ ﯾﺴﻮي؟ ﺑﯿﻌﻄﯿﻬﻢ ﻓﯿﺘﺎﻣﯿﻦ there is deficiency of factor five and prolongation of INR, so !ﻃﺮﯾﻖ اﻟﻔﻢ ﺑﯿﻄﻠﻊ ﻣﺎ ﯾﺴﺘﻔﯿﺪ ﻣﻨﻪ اﻟﻤﺮﯾﺾ، ﻻزم ﺗﻌﻄﻮﻧﻪ اﻧﺠﻜﺸﻦ ﻣﻮﻻزم ﺗﻌﺮﻓﻮن اﻟﻬﺎﻓﻼﯾﻒ 1/Detailed patient & family medical history (crucial & vital regardless of the prior lab testing) ​ ​ •Establish likelihood of a bleeding disorder​ • Guide laboratory Testing -Did bleeding occur: •Early in the newborn period (circumcision) ​ ​ •After hemostatic Challenges ( delivery, injury, trauma, surgery, invasive dental ​ ​ procedure, menstruation ) -Frequency & pattern -Duration: •Onset ( congenital vs. acquired ) ​ ​ •Time required for cessation ​ -Sites of bleeding (specific or multiple): Sites of bleeding Mucocutaneous Bleeding Deep Tissue Bleeding ‘Primary Hemostasis Defects ‘Secondary Hemostasis Defects ( PLT or vW Factor )’ ( Clotting Factors Deficiencies )’ •Easy bruising •Joints •Epistaxis •Muscles •Menorrhagia •Central Nervous System - Current use of medications or herbal supplements ​ ​ - Use of Bleeding Assessment Tools (differentia bleeding phenotypes, require validation by prospective studies) 2/Laboratory Testing: Screening Tests: 1.CBC (Platelet count) ​ ​ 2.Prothrombin Time (PT) → measures FVII, X, V, II, I - (normal time 10-14 secs) “extrinsic pathway” ​ ​ ​ ​ 3.International Normalized Ratio (INR) → the ratio of a patient's PT to a normal (control) sample, raised to ​ ​ the power of the ISI (international sensitivity index) value for the control sample used. 4.Activated Partial Thromboplastin Time (aPTT or PTT) → measures F XII, XI, IX, VIII, X, ​ ​ V, II, I - (normal Time 30 – 40 secs) “intrinsic pathway” 5.Thrombin (Clotting) Time (TT) → sensitive to deficiency of Fibrinogen or inhibition of thrombin - (normal ​ ​ Time 14 – 16 secs) 6.Bleeding Time → (3-8 secs) (not sensitive – not specific ) ​ ​ -Screening tests (not sensitive to all abnormalities associated with a bleeding disorder) -Although screening tests are used widely to identify hemostatic abnormalities associated with bleeding, they are NOT perfect -The Clinical suspicion for a bleeding disorder is Critical to determine extent of the laboratory ​ ​ investigations Specialized Tests 1.Mixing Study (one to one mixture of patient’s plasma & known normal standard plasma, only if PT or ​ ​ ​ ​ ​ ​ aPTT prolonged) ​ Corrected → clotting factor deficiency (risk of bleed) ​ Not corrected → inhibitors
Load more

Recommended publications
  • Evans Syndrome As Rare Presentation in Systemic Lupus Erythematosus
    International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Case Report Evans Syndrome as Rare Presentation in Systemic Lupus Erythematosus Dr Sabarish Mahalingam1, Dr P. Z. Wadia2, Dr Priyanka Lad1 1Resident Doctor, Department of Internal Medicine, Government Medical College, Surat 2Additional Professor, Department of Internal Medicine, Government Medical College, Surat Corresponding Author: Dr Sabarish Mahalingam ABSTRACT Evans syndrome is a rare disorder in which the body’s immune system produces antibodies that mistakenly destroy red blood cells, platelets and sometimes certain white blood cell known as neutrophils. It is one of the rare presenting features of autoimmune disorders, especially systemic lupus erythematosus (SLE), and sometimes may even precede the onset of disease. Primary Evans syndrome with no cause is very rare and is seen in children. Here, we describe a case of secondary Evans syndrome with severe autoimmune hemolytic anemia leading to acute kidney injury. This is one of the rare presentations of SLE and there are only few case reports. Key word: Evans syndrome, systemic lupus erythematosus, autoimmune haemolytic anaemia. INTRODUCTION literature; [9-11] therefore, the characteristics Evans syndrome (ES), which was and outcome of adult's ES are poorly first described in 1951, is an autoimmune known. disorder characterized by the simultaneous or sequential development of autoimmune CASE REPORT hemolytic anemia (AIHA) and immune A 28 aged female came to (ITP) and/or immune neutropenia in the emergency department with the complain of absence of any underlying cause. [1,2] ES has breathlessness for past 5 days. On been since its first description considered or examination, patient was pale and defined as an “idiopathic” condition and tachypneic, systemic examination was thus mainly as a diagnosis of exclusion, ES normal.
    [Show full text]
  • High Prevalence of Sticky Platelet Syndrome in Patients with Infertility and Pregnancy Loss
    Journal of Clinical Medicine Article High Prevalence of Sticky Platelet Syndrome in Patients with Infertility and Pregnancy Loss Eray Yagmur 1,* , Eva Bast 2, Anja Susanne Mühlfeld 3, Alexander Koch 4, Ralf Weiskirchen 5 , Frank Tacke 6 and Joseph Neulen 7 1 Medical Care Center, Dr. Stein and Colleagues, D-41169 Mönchengladbach, Germany 2 Department of Gynecology and Obstetrics, Bürgerhospital Frankfurt, D-60318 Frankfurt, Germany 3 Division of Nephrology and Clinical Immunology,RWTH-University Hospital Aachen, D-52074 Aachen, Germany 4 Department of Medicine III, RWTH-University Hospital Aachen, D-52074 Aachen, Germany 5 Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry, RWTH-University Hospital Aachen, D-52074 Aachen, Germany 6 Department of Hepatology and Gastroenterology,Charité University Medical Center, D-10117 Berlin, Germany 7 Department of Gynecological Endocrinology and Reproductive Medicine, RWTH-University Hospital Aachen, D-52074 Aachen, Germany * Correspondence: [email protected]; Tel.: +49-2161-8194-442 Received: 26 July 2019; Accepted: 26 August 2019; Published: 28 August 2019 Abstract: Platelet hyperaggregability, known as sticky platelet syndrome (SPS), is a prothrombotic disorder that has been increasingly associated with pregnancy loss. In this retrospective study, we aimed to investigate the clinical and diagnostic relevance of SPS in 208 patients with infertility and unexplained pregnancy loss history. We studied 208 patients that had been referred to undergo a dose-dependent platelet aggregation response to adenosine diphosphate and epinephrine using light transmission aggregometry modified by Mammen during an 11-year period. Patients’ platelet aggregation response was compared with platelet function in 29 female healthy controls of fertile age with no previous history of pregnancy loss.
    [Show full text]
  • MYH9-Related Platelet Disorders
    Reprinted with permission from Thieme Medical Publishers (Semin Thromb Hemost 2009;35:189-203) Homepage at www.thieme.com MYH9-Related Platelet Disorders Karina Althaus, M.D.,1 and Andreas Greinacher, M.D.1 ABSTRACT Myosin heavy chain 9 (MYH9)-related platelet disorders belong to the group of inherited thrombocytopenias. The MYH9 gene encodes the nonmuscle myosin heavy chain IIA (NMMHC-IIA), a cytoskeletal contractile protein. Several mutations in the MYH9 gene lead to premature release of platelets from the bone marrow, macro- thrombocytopenia, and cytoplasmic inclusion bodies within leukocytes. Four overlapping syndromes, known as May-Hegglin anomaly, Epstein syndrome, Fechtner syndrome, and Sebastian platelet syndrome, describe different clinical manifestations of MYH9 gene mutations. Macrothrombocytopenia is present in all affected individuals, whereas only some develop additional clinical manifestations such as renal failure, hearing loss, and presenile cataracts. The bleeding tendency is usually moderate, with menorrhagia and easy bruising being most frequent. The biggest risk for the individual is inappropriate treatment due to misdiagnosis of chronic autoimmune thrombocytopenia. To date, 31 mutations of the MYH9 gene leading to macrothrombocytopenia have been identified, of which the upstream mutations up to amino acid 1400 are more likely associated with syndromic manifestations than the downstream mutations. This review provides a short history of MYH9-related disorders, summarizes the clinical and laboratory character- istics, describes a diagnostic algorithm, presents recent results of animal models, and discusses aspects of therapeutic management. KEYWORDS: MYH9 gene, nonmuscle myosin IIA, May-Hegglin anomaly, Epstein syndrome, Fechtner syndrome, Sebastian platelet syndrome, macrothrombocytopenia The correct diagnosis of hereditary chronic as isolated platelet count reductions or as part of thrombocytopenias is important for planning appropri- more complex clinical syndromes.
    [Show full text]
  • Case Report Treatment of Severe Evans Syndrome with an Allogeneic Cord Blood Transplant
    Bone Marrow Transplantation, (1997) 20, 427–429 1997 Stockton Press All rights reserved 0268–3369/97 $12.00 Case report Treatment of severe Evans syndrome with an allogeneic cord blood transplant E Raetz1, PG Beatty2 and RH Adams1 Departments of 1Pediatrics and 2Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA Summary: began experiencing increased difficulty with mucosal bleeding, which prompted frequent platelet transfusions. At Immunosuppressive therapy is commonly used in the 4. years, he had a major gastrointestinal bleed, followed management of autoimmune disorders. As marrow- 1 month later by an intracranial hemorrhage. He required derived lymphocytes appear to play a key role in these transient ventilator support, but eventually regained full diseases, lymphoid ablation followed by replacement neurologic function. Direct (DAT) and indirect (IAT) with autologous or allogeneic stem cells may be a thera- Coombs evaluations were always 3+ positive. Due to the peutic option. We report a 5-year-old boy with severe severe and refractory nature of his disease, the option of Evans syndrome which consists of immune thrombocy- novel therapy with bone marrow transplantation was topenia and Coombs-positive hemolytic anemia. He was pursued. rendered into complete remission with marrow ablation HLA typing of the family, and a search of the unrelated followed by rescue with an HLA-identical sibling cord marrow donor registries, did not identify an appropriate blood transplant. He unexpectedly died 9 months donor, but DNA-based typing for HLA-A, -B, -DRB1 of following transplant from acute hepatic failure of the amniotic fluid of a sibling fetus, of 6 months gestational unknown etiology.
    [Show full text]
  • Sticky Platelet Syndrome
    SEMINARS IN THROMBOSIS AND HEMOSTASIS—VOL. 25, NO. 4, 1999 Sticky Platelet Syndrome EBERHARD F. MAMMEN, M.D. ABSTRACT The sticky platelet syndrome (SPS) is an autosomal dominant platelet disorder associated with arterial and venous thromboembolic events. It is characterized by hyperaggregability of platelets in platelet-rich plasma with adenosine diphosphate (ADP) and epinephrine (type I), epinephrine alone (type II), or ADP alone (type III). Clinically, patients may present with angina pectoris, acute myocardial infarc• tion (MI), transient cerebral ischemic attacks, stroke, retinal thrombosis, peripheral arterial thrombosis, and venous thrombosis, frequently recurrent under oral anticoagulant therapy. Clinical symptoms, espe• cially arterial, often present following emotional stress. Combinations of SPS with other congenital throm- bophilic defects have been described. Low-dose aspirin treatment (80 to 100 mg) ameliorates the clinical symptoms and normalizes hyperaggregability. The precise etiology of this defect is at present not known, but receptors on the platelet surface may be involved. Normal levels of platelet factor 4 (PF4) and p-throm- boglobulin in plasma suggest that the platelets are not activated at all times; they appear to become hyper• active upon ADP or adrenaline release. In vivo clumping could temporarily or permanently occlude a ves• sel, leading to the described clinical manifestations. The syndrome appears to be prominent especially in patients with unexplained arterial vascular occlusions. Keywords: Platelets,
    [Show full text]
  • Case Report Evans Syndrome
    Bangladesh Med J. 2018 Sept; 47(3) Case Report Evans Syndrome: A Case Report *Biswas SK1, BiswasT2, Khondoker N3, Alam MR4, Rahim MA5, Paul HK6, Shahin MA7, Hasan MN 8, Bhuiyan AKMM9 Abstract: INTRODUCTION Evans syndrome, a combined clinical condition of autoimmune Evans syndrome is an uncommon clinical condition de!ned haemolytic anaemia (AHA) and idiopathic thrombocytopaenic by the combination of autoimmune hemolytic anemia 1 purpura (ITP) and has non-speci!c pathogenesis. "e clinical (AHA) and idiopathic thrombocytopenic purpura (ITP). It cases are extremely rare, since only 4% of AHA or ITP are is a chronic immune- associated disease which has unknown incorporated with Evans. It is distinguished from di#erentials, pathophysiology. "e true Evans syndrome is diagnosed such as lupus, IgA de!ciency, and acquired immunode!ciency, when possibility of other confounding disorders is excluded. by peripheral blood !lm, bone marrow, Coombs test, and In 1951, Dr. Robert Evan discovered the spectrum like coagulation pro!le. A case of adult female from Pabna, relationship between these two combined diseases after 1 Bangladesh is documented in this report. She complained of studying twenty-four cases. Epidemiologically, the high grade intermittent fever, exertional dyspnea, icteric skin condition is extremely rare that only less than 4% of ITP or 2-5 and sclera. Other features included mild splenomegaly, dark AHA are diagnosed as Evans syndrome. "ere is evidence urine, and profuse sweating after fever. Investigation reports of both cellular and humoral immune-abnormalities in 6 were consistent with AHA and ITP, with normal coagulation Evans syndrome. Di#erent scientists provided di#erent and viral pro!le.
    [Show full text]
  • Diagnosis of Inherited Platelet Disorders on a Blood Smear
    Journal of Clinical Medicine Article Diagnosis of Inherited Platelet Disorders on a Blood Smear Carlo Zaninetti 1,2,3 and Andreas Greinacher 1,* 1 Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, 17489 Greifswald, Germany; [email protected] 2 University of Pavia, and IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy 3 PhD Program of Experimental Medicine, University of Pavia, 27100 Pavia, Italy * Correspondence: [email protected]; Tel.: +49-3834-865482; Fax: +49-3834-865489 Received: 19 January 2020; Accepted: 12 February 2020; Published: 17 February 2020 Abstract: Inherited platelet disorders (IPDs) are rare diseases featured by low platelet count and defective platelet function. Patients have variable bleeding diathesis and sometimes additional features that can be congenital or acquired. Identification of an IPD is desirable to avoid misdiagnosis of immune thrombocytopenia and the use of improper treatments. Diagnostic tools include platelet function studies and genetic testing. The latter can be challenging as the correlation of its outcomes with phenotype is not easy. The immune-morphological evaluation of blood smears (by light- and immunofluorescence microscopy) represents a reliable method to phenotype subjects with suspected IPD. It is relatively cheap, not excessively time-consuming and applicable to shipped samples. In some forms, it can provide a diagnosis by itself, as for MYH9-RD, or in addition to other first-line tests as aggregometry or flow cytometry. In regard to genetic testing, it can guide specific sequencing. Since only minimal amounts of blood are needed for the preparation of blood smears, it can be used to characterize thrombocytopenia in pediatric patients and even newborns further.
    [Show full text]
  • Controversies in Thrombosis and Hemostasis Part 2–Does Sticky Platelet Syndrome Exist?
    Published online: 2019-01-10 Commentary 69 Commentary: Controversies in Thrombosis and Hemostasis Part 2–Does Sticky Platelet Syndrome Exist? Emmanuel J. Favaloro, PhD, FFSc (RCPA)1 Giuseppe Lippi, MD2 1 Department of Haematology, Sydney Centres for Thrombosis and Address for correspondence Emmanuel J. Favaloro, PhD, FFSc (RCPA), Haemostasis, Institute of Clinical Pathology and Medical Research, Department of Haematology, Institute of Clinical Pathology and Westmead Hospital, Westmead, NSW, Australia Medical Research (ICPMR), Westmead Hospital, Westmead, NSW, 2 Section of Clinical Biochemistry, University of Verona, Verona, Italy Australia (e-mail: [email protected]). Semin Thromb Hemost 2019;45:69–72. Hemostasis ¼ love. plasma coagulation system (including clot formation).1 Although this provides a convenient separation to help teach Everyone talks about, but no one understands it. hemostasis to junior scientists, and to study this process in vitro, it needs to be recognized that, in vivo at least, these Hemostasis is complex. The process of hemostasis has sev- systems do not work in isolation. Primary and secondary eral outcomes, including physiologically arresting blood loss hemostasis work in concert to form the platelet plug. Injury at sites of vascular injury. In simple terms, this is achieved by to a blood vessel causes a cascade of events. The injury formation of a “plug that seals the hole.” This “plug” com- releases cellular components including “tissue factor,” as prises a framework of blood components that act together to well as exposing subendothelial surfaces that are normally create a stable mass that stops further blood leakage. not exposed to this blood. This causes activation of “second- Hemostasis involves the complex interaction of many ary hemostasis” by several mechanisms.
    [Show full text]
  • Gri Trombosit Sendromu
    Cukurova Medical Journal Cukurova Med J 2017;42(2):360-362 ÇUKUROVA ÜNİVERSİTESİ TIP FAKÜLTESİ DERGİSİ DOI: 10.17826/cutf.322967 OLGU SUNUMU / CASE REPORT Gray platelet syndrome Gri trombosit sendromu Fatima Ayaz1, Saeed Bin Ayaz2, Sunila Tashfeen2, Muhammad Furrukh1 1Benazir Bhutto Hospital, Rawalpindi, Punjab, Pakistan 2Combined Military Hospital, Okara, Punjab, Pakistan Cukurova Medical Journal 2017;42(2):360-362 Abstract Öz Gray platelet syndrome (GPS) is an autosomal recessive Gri trombosit (platelet) sendromu (GPS), trombositopeni disorder characterized by thrombocytopenia and defective ve ışık mikroskopunda soluk görünen kusurlu platelets that appear pale on light microscope. Patients trombositlerle karakterize, otozomal resesif geçişli bir present with easy bruisability, nose bleeds, menorrhagia hastalıktır. Hastalarda kolay morarma, burun kanaması, and prolonged bleeding. There is no specific treatment for menoraji ve uzun kanamalar görülmektedir. GPS için GPS and the management includes anticipating risks and spesifik bir tedavi bulunmamaktadır dolayısı ile hastalığa preventing bleeding by avoiding drugs that impair platelet karşı, riskleri öngörmek ve kanamanın önlenmesi function. We present here report of a case who presented için trombosit fonksiyonunu bozan ilaçlardan kaçınmak with repeated episodes of abnormal bleeding and was gerekmektedir. Bu olgu sunumunda, tekrarlayan anormal found to have GPS. kanama atakları olan ve GPS bulgusu bulunan bir vaka sunulmaktadır. Key words: Bleeding disorder, gray platelet syndrome, Anahtar
    [Show full text]
  • ISTH Couverture 6.6.2012 10:21 Page 1 ISTH Couverture 6.6.2012 10:21 Page 2 ISTH Couverture 6.6.2012 10:21 Page 3 ISTH Couverture 6.6.2012 10:21 Page 4
    ISTH Couverture 6.6.2012 10:21 Page 1 ISTH Couverture 6.6.2012 10:21 Page 2 ISTH Couverture 6.6.2012 10:21 Page 3 ISTH Couverture 6.6.2012 10:21 Page 4 ISTH 2012 11.6.2012 14:46 Page 1 Table of Contents 3 Welcome Message from the Meeting President 3 Welcome Message from ISTH Council Chairman 4 Welcome Message from SSC Chairman 5 Committees 7 ISTH Future Meetings Calendar 8 Meeting Sponsors 9 Awards and Grants 2012 12 General Information 20 Programme at a Glance 21 Day by Day Scientific Schedule & Programme 22 Detailed Programme Tuesday, 26 June 2012 25 Detailed Programme Wednesday, 27 June 2012 33 Detailed Programme Thursday, 28 June 2012 44 Detailed Programme Friday, 29 June 2012 56 Detailed Programme Saturday, 30 June 2012 68 Hot Topics Schedule 71 ePoster Sessions 97 Sponsor & Exhibitor Profiles 110 Exhibition Floor Plan 111 Congress Centre Floor Plan www.isth.org ISTH 2012 11.6.2012 14:46 Page 2 ISTH 2012 11.6.2012 14:46 Page 3 WelcomeCommittees Messages Message from the ISTH SSC 2012 Message from the ISTH Meeting President Chairman of Council Messages Dear Colleagues and Friends, Dear Colleagues and Friends, We warmly welcome you to the elcome It is my distinct privilege to welcome W Scientific and Standardization Com- you to Liverpool for our 2012 SSC mittee (SSC) meeting of the Inter- meeting. national Society on Thrombosis and Dr. Cheng-Hock Toh and his col- Haemostasis (ISTH) at Liverpool’s leagues have set up a great Pro- UNESCO World Heritage Centre waterfront! gramme aiming at making our off-congress year As setting standards is fundamental to all quality meeting especially attractive for our participants.
    [Show full text]
  • Platelet Function Disorders
    TREATMENT OF HEMOPHILIA APRIL 2008 • NO 19 PLATELET FUNCTION DISORDERS Second Edition Anjali A. Sharathkumar Amy Shapiro Indiana Hemophilia and Thrombosis Center Indianapolis, U.S.A. Published by the World Federation of Hemophilia (WFH), 1999; revised 2008. © World Federation of Hemophilia, 2008 The WFH encourages redistribution of its publications for educational purposes by not-for-profit hemophilia organizations. In order to obtain permission to reprint, redistribute, or translate this publication, please contact the Communications Department at the address below. This publication is accessible from the World Federation of Hemophilia’s website at www.wfh.org. Additional copies are also available from the WFH at: World Federation of Hemophilia 1425 René Lévesque Boulevard West, Suite 1010 Montréal, Québec H3G 1T7 CANADA Tel. : (514) 875-7944 Fax : (514) 875-8916 E-mail: [email protected] Internet: www.wfh.org The Treatment of Hemophilia series is intended to provide general information on the treatment and management of hemophilia. The World Federation of Hemophilia does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. Dose schedules and other treatment regimes are continually revised and new side effects recognized. WFH makes no representation, express or implied, that drug doses or other treatment recommendations in this publication are correct. For these reasons it is strongly recommended that individuals seek the advice of a medical adviser and/or consult printed instructions provided by the pharmaceutical company before administering any of the drugs referred to in this monograph. Statements and opinions expressed here do not necessarily represent the opinions, policies, or recommendations of the World Federation of Hemophilia, its Executive Committee, or its staff.
    [Show full text]
  • 503 © Springer Nature Switzerland AG 2021 D. M. Kamat, M. Frei
    Index A Acute splenic sequestration crisis (ASSC), 71 Abnormal chromosomal breakage test, 387 Adenosine deaminase activity (ADA), 372 ABO hemolytic disease, 325 Allo-immune thrombocytopenia, 116 Acquired aplastic anemia (AAA) Alternative pathway, 489 clinical features, 371 Anemia, 323, 326 definition and classifications, 371 chronic disease, 375, 376 diagnosis and management, 371 congenital dyserythropoietic anemias, 381 etiology and pathogenesis, 371 fanconi anemia, 374, 375 incidence, 370 folic acid deficiency, 380, 381 Acquired disorders of coagulation iron deficiency anemia, 377–379 coaguloapathy vitamin B12 deficiency, 379, 380 liver failure, 264 ANKRD26-related thrombocytopenia massive transfusion, 264, 265 (ANKRD26-RT), 143 disseminated intravascular Anticoagulation therapy, 348–350 coagulation, 261–263 Antiphospholipid antibodies (APAs), 273 platelet dysfunction, renal failure, 263 Antithrombin (AT) deficiency, 272 sepsis Aplastic anemia (AA) consensus definition, 259 clinical presentation, 393 multiple hematologic diagnosis and severity stratification, manifestations, 259 393, 395 organ injury, 260 differential diagnosis, 393 pathogenesis, 260 eltrombopag, 397 TAMOF, 261 epidemiology, 391 TTP, 261 etiology, 392 Acquired thromboembolic events, 346 hematopoietic stem cell transplant, 398 Acquired von Willebrand Syndrome (AVWS) idiopathic AA, 391 definition, 240 immunosuppressive therapy, 396 diagnosis, 240–242 infection prevention and treatment, 396 management, 242–244 pathophysiology, 392 pathophysiology, 240 transfusion support,
    [Show full text]